Status:
COMPLETED
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Hepatitis C, Chronic
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This randomized, open-label, active-controlled, parallel-group study will evaluate the sustained virological response of danoprevir boosted with low dose ritonavir in combination with Pegasys (peginte...
Eligibility Criteria
Inclusion
- Adults patients, \>/=18 years of age
- Chronic Hepatitis C, Genotype 1 and 4
- HCV RNA \>/=50,000 IU/mL
- treatment-naive
Exclusion
- Patients with cirrhosis or incomplete/transition to cirrhosis
- Patients with other forms of liver disease, HIV infection, hepatocellular carcinoma or severe cardiac disease
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
421 Patients enrolled
Trial Details
Trial ID
NCT01220947
Start Date
November 1 2010
End Date
December 1 2012
Last Update
November 2 2016
Active Locations (68)
Enter a location and click search to find clinical trials sorted by distance.
1
La Jolla, California, United States, 92037-1030
2
Sacramento, California, United States, 95817
3
San Diego, California, United States, 92154
4
San Francisco, California, United States, 94143